Pharmaceutical giant Adcock Ingram has confirmed its delisting from the Johannesburg Stock Exchange (JSE) on 11 November 2025. The move marks the end of its 17-year run as a public company. This follows the finalisation of a R4.2 billion acquisition scheme by the Indian-based Natco Pharma. The company announced that it had fulfilled or waived all conditions precedent for the…
Tag: Delisting
-
Ascendis to Delist from the Johannesburg Stock Exchange
Health group Ascendis Health plans a significant change. The company will delist from the Johannesburg Stock Exchange (JSE). It has made a conditional offer to its investors. Ascendis will repurchase shares from them. The market reacted very positively to this news. The company’s stock price surged by 13.4%. This move to delist Ascendis is a key part of its new strategy. The…
-
Adcock Ingram Reports Flat Profit Despite Winter Surge
Pharmaceutical giant Adcock Ingram has announced flat annual profits despite a significant recovery in the second half of its financial year. This was buoyed by strong demand for its popular over-the-counter winter medicines. In a landmark move, the maker of household staples like Panado and Corenza-C is also set to delist from the Johannesburg Stock Exchange (JSE). This follows a…